BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25202052)

  • 1. Serum EpCAM expression in pancreatic cancer.
    Gebauer F; Struck L; Tachezy M; Vashist Y; Wicklein D; Schumacher U; Izbicki JR; Bockhorn M
    Anticancer Res; 2014 Sep; 34(9):4741-6. PubMed ID: 25202052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sergeant G; Roskams T; van Pelt J; Houtmeyers F; Aerts R; Topal B
    BMC Cancer; 2011 Jan; 11():47. PubMed ID: 21281486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survivin expression and serum levels in pancreatic cancer.
    Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W
    World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
    Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.
    Nishio K; Kimura K; Amano R; Nakata B; Yamazoe S; Ohira G; Miura K; Kametani N; Tanaka H; Muguruma K; Hirakawa K; Ohira M
    World J Gastroenterol; 2017 Aug; 23(31):5764-5772. PubMed ID: 28883702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule EpCAM (GA733-2), and carbohydrate antigen 19-9 (CA 19-9) levels in colorectal cancer patients and correlation with clinicopathological characteristics.
    Mourtzikou A; Stamouli M; Kroupis C; Christodoulou S; Skondra M; Kastania A; Pectasides D; Athanasas G; Dimas C
    Clin Lab; 2012; 58(5-6):441-8. PubMed ID: 22783573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
    Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma.
    Yang Z; Senninger N; Flammang I; Ye Q; Dhayat SA
    J Cancer Res Clin Oncol; 2019 May; 145(5):1165-1178. PubMed ID: 30778748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB
    J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of serum survivin in patients with pancreatic ductal adenocarcinoma.
    Ren YQ; Zhang HY; Su T; Wang XH; Zhang L
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):3063-8. PubMed ID: 25392106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.
    Rychlíková J; Vecka M; Jáchymová M; Macášek J; Hrabák P; Zeman M; Vávrová L; Řoupal J; Krechler T; Ák A
    Cancer Biomark; 2016 Jun; 17(1):55-65. PubMed ID: 27314293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer.
    Peng HY; Chang MC; Hu CM; Yang HI; Lee WH; Chang YT
    Ann Surg Oncol; 2019 Mar; 26(3):807-814. PubMed ID: 30569296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels.
    Seifert AM; Reiche C; Heiduk M; Tannert A; Meinecke AC; Baier S; von Renesse J; Kahlert C; Distler M; Welsch T; Reissfelder C; Aust DE; Miller G; Weitz J; Seifert L
    Oncogene; 2020 Apr; 39(15):3102-3113. PubMed ID: 32055023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
    Benko G; Spajić B; Krušlin B; Tomas D
    Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay.
    Liberati D; Marzinotto I; Brigatti C; Dugnani E; Pasquale V; Reni M; Balzano G; Falconi M; Piemonti L; Lampasona V
    Cancer Biomark; 2018; 22(2):351-357. PubMed ID: 29660901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer.
    Felix K; Hinz U; Dobiasch S; Hackert T; Bergmann F; Neumüller M; Gronowitz S; Bergqvist M; Strobel O
    Pancreas; 2018 Jan; 47(1):72-79. PubMed ID: 29189449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.